

Supplemental Information

Figure S1. QQ plots of the GWASs. (a) QQ plot of GWAS in individuals of European ancestry. (b) QQ plot of combined GWAS meta-analysis of all individuals.




Table S1. Characteristics of active surveillance patients included in the discovery and replication genome-wide association study.

	Discovery		Replication			
	European	African	Asian	Latin American	European ^a	
Ancestral population						
Sample size	5,222	396	237	81	425	
Mean age (\pm s.d.)	63.5 (\pm 7.2)	62 (\pm 8.2)	63.8 (\pm 7.7)	63 (\pm 7.2)	64.4 (\pm 8.2)	
Median follow-up time (months, IQR)	80 (51,112)	68 (40,106)	86 (54,118)	59 (33,85)	80 (31,110)	
Gleason grade						
GG1	4,819 (92%)	359 (91%)	219 (92%)	77 (95%)	372 (87%)	
GG2	344 (7%)	32 (8%)	15 (6%)	4 (5%)	48 (11%)	
\geq GG3	55 (1%)	4 (1%)	3 (1%)	0 (0%)	5 (1%)	
PSA (MAD)	5.0 (\pm 2.1)	5.3 (\pm 2.0)	5.3 (\pm 2.5)	4.7 (\pm 2.4)	4.1 (\pm 2.2)	
Clinical tumor stage						
cT1	4,138 79%	322 81%	161 68%	66 81%	372 88%	
cT2	641 12%	49 12%	39 16%	9 11%	53 12%	
cT3 or cT4	34 1%	5 1%	5 2%	1 1%	0 0%	
Number of cores						
1-2	4,113 (79%)	298 (75%)	177 (75%)	67 (83%)	386 (91%)	
3	451 (9%)	44 (11%)	20 (8%)	7 (9%)	27 (6%)	
\geq 4	522 (10%)	39 (10%)	37 (16%)	7 (9%)	12 (3%)	
PC risk category						
Low	3,639 (70%)	262 (66%)	141 (59%)	59 (73%)	314 (74%)	
Intermediate	983 (19%)	82 (21%)	53 (22%)	14 (17%)	91 (21%)	
High	599 (11%)	52 (13%)	43 (18%)	8 (10%)	20 (5%)	

a. MD Anderson samples of European Ancestry.

IQR, interquartile range; MAD, median absolute deviation; PSA, prostate-specific antigen; PC, prostate cancer. Men of genetically inferred European ancestry genotyped by CIDR are included in the discovery GWAS. The other participants genotyped by CIDR and men from MD Anderson are included in the replication.

Age and cancer clinical characteristics were measured at diagnosis.

PC risk categories:

Low-risk patients had all the following criteria: GG1 only (Gleason \leq 3+3), PSA <10 ng/mL, clinical stage T1, and \leq 3 positive biopsy cores.

Intermediate-risk patients had any of the following, with no high-risk criteria: GG2 (Gleason 3+4), PSA 10-20 ng/mL, or clinical stage T2.

High-risk patients had any of the following: \geq GG3 (\geq Gleason 4+3), PSA \geq 20 ng/mL, clinical stage \geq T3, or \geq 4 positive biopsy cores.

Percentages do not all sum to 100% due to missingness.

Table S2. Hazard ratios for the association between time to AS failure with prostate cancer GRS.

	Minimally Adjusted			Fully Adjusted		
	HR ^a	95% CI	P	HR ^b	95% CI	P
Decile						
0-10	0.73	0.60, 0.89	0.0016	0.69	0.56, 0.86	0.0010
10-20	0.81	0.68, 0.98	0.030	0.83	0.68, 1.01	0.067
20-30	0.93	0.78, 1.11	0.44	0.99	0.82, 1.20	0.95
30-40	0.83	0.69, 0.99	0.041	0.82	0.67, 0.99	0.043
40-60	1.00	Reference		1.00	Reference	
60-70	1.06	0.89, 1.26	0.50	1.03	0.86, 1.24	0.72
70-80	1.10	0.92, 1.30	0.30	1.02	0.85, 1.22	0.87
80-90	1.23	1.04, 1.46	0.014	1.15	0.96, 1.37	0.13
90-100	1.27	1.07, 1.51	0.0061	1.13	0.94, 1.36	0.18

HR = Hazard Ratio; CI = Confidence Interval

^a Hazard ratios are adjusted for age and the first 10 genetic principal components

^b Hazard ratios are adjusted for age, the first 10 genetic principal components, Gleason grade group (GG1, GG2, or \geq GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and number of positive biopsy cores (1-2, 3, or \geq 4).

Table S3. Hazard ratios for the association between time to AS failure with prostate-specific antigen GRS.

	Minimally Adjusted			Fully Adjusted		
	HR ^a	95% CI	P	HR ^b	95% CI	P
Decile						
0-10	1.28	1.08, 1.52	0.0044	1.25	1.04, 1.50	0.017
10-20	1.08	0.90, 1.29	0.40	1.01	0.83, 1.22	0.96
20-30	1.15	0.97, 1.37	0.11	1.18	0.98, 1.42	0.083
30-40	1.16	0.98, 1.38	0.088	1.16	0.96, 1.39	0.12
40-60	1.00	Reference		1.00	Reference	
60-70	1.08	0.90, 1.29	0.40	1.05	0.86, 1.27	0.65
70-80	1.00	0.83, 1.19	0.96	0.96	0.79, 1.17	0.70
80-90	0.98	0.82, 1.18	0.84	1.02	0.84, 1.24	0.87
90-100	0.95	0.79, 1.15	0.60	0.97	0.79, 1.19	0.78

HR = Hazard Ratio; CI = Confidence Interval

^a Hazard ratios are adjusted for age and the first 10 genetic principal components

^b Hazard ratios are adjusted for age, the first 10 genetic principal components, Gleason grade group (GG1, GG2, or ≥ GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and number of positive biopsy cores (1-2, 3, or ≥ 4).

Table S4. ROC analysis of PC and PSA GRS compared to clinical characteristics for conversion from AS to treatment.

Model	GRS _{PC} ^d			GRS _{PSA} ^d			AUC
	HR	95% CI	P-value	HR	95% CI	P-value	
Reference model ^a							0.550
PC clinical characteristics ^b							0.653
PC clinical characteristics + PC GRS ^c	1.13	1.07, 1.19	3.3×10^{-6}				0.659
PC clinical characteristics + PSA GRS ^c				0.94	0.89, 0.98	8.5×10^{-3}	0.655
PC clinical characteristics + PC GRS + PSA GRS	1.15	1.09, 1.22	1.5×10^{-7}	0.91	0.87, 0.96	3.0×10^{-4}	0.661

^a All models contain age and the first 10 principal components.

^b PC clinical characteristics were Gleason grade group (GG1, GG2, or \geq GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and number of positive biopsy cores (1-2, 3, or \geq 4).

^c PC GRS is constructed from 269 prostate cancer associated variants, while PSA GRS is derived from 36 PSA risk variants.

^d The test statistics of GRS_{PC} and GRS_{PSA} are reported when the model contains them.